A pan-affinity resin for efficient AAV purification: a CDMO perspective

Cell & Gene Therapy Insights 2022; 8(4), 569

DOI: 10.18609/cgti.2022.086

Published: 7 May 2022
Vincent Ravault

Over the last decade, the number of clinical trials involving recombinant adeno-associated viral (AAV) vectors has dramatically increased, the diversity of serotypes has expanded, and the demand for highly purified material manufactured to cGMP standards has rocketed. For contract development and manufacturing organizations (CDMOs) like Yposkesi, the key manufacturing challenges are centered around flexibility, robustness, and productivity, especially with regard to purification. The availability of universal tools to address any serotype with minimal process adjustments is therefore critical. Yposkesi conducted a series of experiments to evaluate the POROS™ CaptureSelect™ AAVX resin, a pan-affinity tool for universal capture of AAV vectors.